Glycopeptides are still the gold standard to treat MRSA (Methicillin Resistant Staphylococcus aureus) infections, but their widespread use has led to vancomycin-reduced susceptibility [heterogeneous Vancomycin-Intermediate-Staphylococcus aureus (hVISA) and Vancomycin-Intermediate-Staphylococcus aureus (VISA)], in which different genetic loci (regulatory, autolytic, cell-wall turnover and cell-envelope positive charge genes) are involved. In addition, reduced susceptibility to vancomycin can influence the development of resistance to daptomycin. Although the phenotypic and molecular changes of hVISA/VISA have been the focus of different papers, the molecular mechanisms responsible for these different phenotypes and for the vancomycin and daptomycin cross-resistance are not clearly understood. The aim of our study was to investigate, by real time RT-PCR, the relative quantitative expression of genes involved in autolysis (atl-lytM), cell-wall turnover (sceD), membrane charges (mprF-dltA) and regulatory mechanisms (agr-locus-graRS-walKR), in hVISA and VISA cultured with or without vancomycin and daptomycin, in order to better understand the molecular basis of vancomycin-reduced susceptibility and the modulating activity of vancomycin and daptomycin on the expression of genes implicated in their reduced susceptibility mechanisms. Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality. Indeed, VISA emerges from hVISA when VISA acquires a reduced autolysis caused by a down-regulation of autolysin genes, atl/lytM, and a reduction of the net negative cell-envelope charge via dltA over-expression. Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin can also induce a charge repulsion mechanism both in hVISA and VISA increasing the activity of the mprF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253798PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029573PLOS

Publication Analysis

Top Keywords

vancomycin daptomycin
24
hvisa visa
24
cell-wall turnover
16
visa
9
modulating activity
8
vancomycin
8
activity vancomycin
8
daptomycin
8
daptomycin expression
8
charge genes
8

Similar Publications

Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.

Eur J Clin Microbiol Infect Dis

January 2025

Neonatal Department of Longyan Division, Tianjin Children's Hospital, Tianjin University Children's Hospital, Tianjin, China.

Objectives: Neonatal sepsis is one of the causes of neonatal mortality and bacterial resistance to antibiotics is one of the challenges facing NICU. The aim of this study was to provide a basis for empirical antibiotic selection by comprehensively searching Chinese and non-Chinese databases for studies related to neonatal sepsis pathogenesis conducted in China and synthesizing all the results of the studies conducted in hospitals in China during the period under study METHODS: In this study, we conducted extensive searches of Pubmed, Web of Science, Cochrane, China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI) and Wanfang Data. We screened studies published from 2014 to 2023 that were conducted in hospitals in mainland China and involved bacterial blood cultures and susceptibility tests in neonates with neonatal sepsis and extracted the data, which were summarized using Stata 18.

View Article and Find Full Text PDF

Polymeric Anti-Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution.

Small

January 2025

Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802, USA.

Vancomycin (VAN) and daptomycin (DAP) are among the last-resort antibiotics for treating multidrug-resistant Gram-positive bacterial infections. They are administered intravenously (IV); however, ≈5 - 10% of the total IV dose is released in the gastrointestinal (GI) tract via biliary excretion, driving resistance emergence in commensal Enterococcus faecium (E. faecium) populations.

View Article and Find Full Text PDF

Background: Kyphoplasty (KP) is a well-established procedure with a low complication risk, however, the procedure's safety in patients with comorbidities and in the setting of systemic infection remains uncertain with no clear guidelines. We present a unique case of KP in the setting of recurrent septicemia, which required subsequent salvage vertebrectomy.

Case Description: We present a clinical case of a 59-year-old diabetic male patient with a recent foot ulcer, positive for and .

View Article and Find Full Text PDF

Objectives: To evaluate the antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.

Methods: Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards.

View Article and Find Full Text PDF

Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia.

Ann Clin Microbiol Antimicrob

January 2025

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health, Charlottesville, Virginia, USA.

Purpose: Monotherapy with vancomycin or daptomycin remains guideline-based care for methicillin-resistant Staphylococcus aureus bacteremia (MRSA-B) despite concerns regarding efficacy. Limited data support potential benefit of combination therapy with ceftaroline as initial therapy. We present an assessment of outcomes of patients initiated on early combination therapy for MRSA-B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!